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High rates of extended-spectrum--lactamase (ESBL)-pro-ducingKlebsiella pneumoniae isolates have been documented
in many Brazilian hospitals, with CTX-M-2 being the most fre-
quent ESBL reported (1). Resistance to broad-spectrum cephalo-
sporins among Enterobacter cloacae isolates is usually due to hy-
perproduction of AmpC; however, production of ESBL represents
an important cause of resistance to these antimicrobial agents
among E. cloacae isolates from Brazilian hospitals (2). PER-2 was
first identified in 1996 in a Salmonella enterica serovar Typhimu-
rium strain isolated from a patient in Argentina who had previ-
ously been hospitalized in 1990 (3). Since then, this enzyme has
also been described in Enterobacteriaceae isolated from Uruguay,
Bolivia, and Argentina and inAcinetobacter spp. and P. aeruginosa
isolates fromArgentina (4–7).Here, we report the first occurrence
of blaPER-2 in Brazil.
In 2006, two cefepime-resistant E. cloacae strains were isolated
from blood cultures of two distinct patients hospitalized in the
Liver Transplant Unit of a tertiary care hospital located in Cu-
ritiba, a southern Brazilian city. Antimicrobial susceptibility test-
ing was interpreted using the CLSI broth microdilution (8)
method, except for polymyxin B, for which the EUCAST criteria
were applied (9). The genetic relatedness of the isolates was eval-
uated by pulsed-field gel electrophoresis (PFGE) using XbaI (10).
Isoelectric focusing analysis was performed with polyacrylamide
gel containing ampholines (Amersham Pharmacia Biotech, Swe-
den; pH range, 3.5 to 9.5). The presence of blaCTX-M-1, -2, -8, -9,
and -25, blaOXA-23, -24, -48, -51, and -58, blaBES, blaTEM, blaSHV, blaPER,
and blaGES was determined by PCR using specific primers (1, 2).
PlasmidDNA (11) and chromosomal DNA (QIAampDNAmini-
kit; Qiagen, Germany) was extracted, and conjugation and trans-
formation were carried out with Escherichia coli J53, E. coliDH5,
and E. coliTOP10 recipient strains. Southern blotting and hybrid-
ization were performed using the digoxigenin (DIG) DNA label-
ing and detection kit (Roche Diagnostics, GmbH, Germany).
Furthermore, both isolates showed susceptibility to polymyxin
B, imipenem, and meropenem and resistance to broad-spectrum
cephalosporins, cefepime, and ertapenem (Table 1). Both isolates
showed the ESBL phenotype by disk approximation test (12).
blaPER-2 and blaTEM-1 were identified in both clinical isolates,
which possessed unique PFGE profiles. Isoelectric focusing anal-
ysis showed a pI of 5.4, which may correspond to the PER-2
and/or TEM-1 pI. Multiple attempts to transfer the blaPER-2 gene
by electroporation and conjugation failed, and hybridization with
blaPER-2- and blaTEM-1-specific probes showed that the blaTEM-1
gene was located on an 140-kb plasmid, while blaPER-2 was lo-
cated on the chromosome in both isolates.
Our study constitutes the first report of PER-2 in Brazil.
blaPER-2 and other PER variant-encoding genes are usually
found on a conjugative plasmid. In contrast, in these E. cloacae
isolates, blaPER-2 was located on the chromosome. The clonal re-
latedness demonstrated by the two E. cloacae clinical isolates sug-
gests that the patients may have acquired these strains from a
common source. Although chromosomal AmpC productionmay
have masked the identification of the ESBL phenotype, both iso-
lates were phenotypically identified as ESBL producers by the disk
approximation test. It probably occurred because the chromo-
somal blaAmpC gene was not derepressed, as shown by the isoelec-
tric focusing results. Althoughmore studies are needed to evaluate
the prevalence of PER-2 amongBrazilian isolates, a previous study
showed that this enzyme was infrequent. It was detected only in
these 2 strains out of 205 Enterobacter species isolates from blood-
stream samples over a 5-year period (2). The reason why PER-2
has not been as frequently detected in Brazil as it is in Argentina, a
neighbor country, remains to be further investigated.
The project was approved by theResearch Ethics Committee of
the Hospital de Clínicas da Universidade Federal do Paraná (pro-
tocol no. 2288.182/2010-07).
(This report was presented in part at the 52th Interscience
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TABLE 1 Antimicrobial susceptibility profiles of two E. cloacae clinical
isolates carrying blaPER-2 and blaTEM-1 in Brazil
Antimicrobial
MIC(s) (mg/liter)a
ECL532 ECL635
Polymyxin B 0.125 0.125
Imipenem 0.25 0.25
Meropenem 0.5 1
Ertapenem 2 2
Amikacin 8 8
Gentamicin 64 64
Cefotaxime 64 128
Ceftazidime 64 64
Cefepime 64 128
Ciprofloxacin 32 32
Levofloxacin 32 32
Aztreonam 32 32
Ticarcillin-clavulanic acid 256,2 256,2
Piperacillin-tazobactan 128,4 128,4
Trimethoprim-sulfamethoxazole 64,1,216 64,1,216
a MICs were determined by the CLSI broth microdilution method.
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